Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard

References

• Ommen SR, Maron BJ, Olivotto I et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.46, 470–476 (2005).
   PubMed Web of Science ®Google Scholar
• McLeod CJ, Ommen SR, Ackerman MJ et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur. Heart J.28, 2583–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Goodwin JF, Hollman A, Cleland WP, Teare D. Obstructive cardiomyopathy simulating aortic stenosis. Br. Heart J.22, 403–414 (1960).
   PubMedGoogle Scholar
• Kirklin JW, Ellis FH Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation24, 739–742 (1961).
   PubMed Web of Science ®Google Scholar
• Bigelow WG, Trimble AS, Auger P, Marquis Y, Wigle ED. The ventriculomyotomy operation for muscular subaortic stenosis. A reappraisal. J. Thorac. Cardiovasc. Surg.4, 514–524 (1966).
   Google Scholar
• Morrow AG. Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J. Thorac. Cardiovasc. Surg.4, 423–430 (1978).
   Google Scholar
• Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathy hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation4, 3–119 (1964).
   Google Scholar
• Maron BJ, Harding AM, Spirito P, Roberts WC, Waller BF. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation68, 282–293 (1983).
   PubMedGoogle Scholar
• Maron MS, Olivotto I, Zenovich AG et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation114, 2232–2239 (2006).
   PubMed Web of Science ®Google Scholar
• Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significant in producing left ventricular outflow obstruction. Circulation84, 1188–1197 (1991).
   PubMed Web of Science ®Google Scholar
• Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum. Pathol.31, 988–998 (2000).
   PubMed Web of Science ®Google Scholar
• Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med.348, 295–303 (2003).
   PubMed Web of Science ®Google Scholar
• Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy – a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol.42, 1687–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br. Heart J.32, 804–811 (1970).
   PubMedGoogle Scholar
• Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation64, 437–441 (1981).
   PubMed Web of Science ®Google Scholar
• Bonow RO, Rosing DR, Bacharach SL et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation64, 787–796 (1981).
   PubMed Web of Science ®Google Scholar
• Rosing DR, Condit JR, Maron BJ et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am. J. Cardiol.48, 545–553 (1981).
   PubMed Web of Science ®Google Scholar
• Sherrid MV, Barac I, McKenna WJ et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.45, 1251–1258 (2005).
   PubMed Web of Science ®Google Scholar
• Melacini P, Maron BJ, Bobbo F et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart93, 708–710 (2007).
   PubMed Web of Science ®Google Scholar
• Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Op. Tech. Thorac. Cardiovasc. Surg.9, 278–292 (2004).
   Google Scholar
• Ommen SR, Park SH, Click RL, Freeman WK, Schaff HV, Tajik AJ. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am. J. Cardiol.90, 1022–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Cooley DA, Leachman RD, Hallman GL, Gerami S, Hall RG. Idiopathic hypertrophic subaortic stenosis. Surgical treatment including mitral valve replacement. Arch. Surg.103, 606–609 (1971).
   PubMedGoogle Scholar
• Cooley DA, Wukasch DC, Leachman RD. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis: results in 27 patients. J. Cardiovasc. Surg.17, 380–387 (1976).
   PubMed Web of Science ®Google Scholar
• Fighali S, Krajcer Z, Leachman RD. Septal myomectomy and mitral valve replacement for idiopathic hypertrophic subaortic stenosis: short- and long-term follow-up. J. Am. Coll. Cardiol.3, 1127–1134 (1984).
   PubMed Web of Science ®Google Scholar
• Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy–myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy: ten-year follow-up in 185 patients. Circulation80, 57–64 (1989).
   Web of Science ®Google Scholar
• Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation85, 1651–1660 (1992).
   PubMed Web of Science ®Google Scholar
• Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J. Thorac. Cardiovasc. Surg.127, 481–489 (2004).
   PubMed Web of Science ®Google Scholar
• Wan CKN, Dearani JA, Sundt TM, Ommen SR, Schaff HV. What is the optimal surgical treatment for obstructive hypertrophic cardiomyopathy and myxomatous mitral regurgitation? Presented at: Society of Thoracic Surgeons Meeting. FL, USA, 27–29 January, 2008.
   Google Scholar
• Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Curr. Probl. Cardiol.29, 233–291 (2004).
   Google Scholar
• Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and the risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med.342, 1778–1785 (2000).
   PubMed Web of Science ®Google Scholar
• Deb SJ, Schaff HV, Dearani JA, Nishimura RA, Ommen SR. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Ann. Thorac. Surg.78, 2118–2122 (2004).
   PubMed Web of Science ®Google Scholar
• Monteiro PF, Ommen SR, Gersh BJ et al. Effects of surgical septal myectomy on left ventricular wall thickness and diastolic filling. Am. J. Cardiol.100, 1776–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Schaff HV, Suri RM, Enriquez-Sarano M. Indications for surgery in degenerative mitral valve disease. Semin. Thorac. Cardiovasc. Surg.19, 97–102 (2007).
   PubMedGoogle Scholar
• Conklin HM, Huang X, Davies CH, Sahn DJ, Shively BK. Biphasic left ventricular outflow and its mechanism in hypertrophic obstructive cardiomyopathy. J. Am. Soc. Echocardiogr.17, 375–383 (2004).
   PubMed Web of Science ®Google Scholar
• Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J. Interv. Cardiol.19, 319–327 (2005).
   Google Scholar
• Singh M, Edwards WD, Holmes DR Jr, Tajik AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin. Proc.76, 799–802 (2001).
   PubMed Web of Science ®Google Scholar
• Faber L, Seggewiss H, Welge D et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur. J. Echocardiogr.5, 347–355 (2004).
   PubMedGoogle Scholar
• Chowdhary S, Galiwango P, Woo A, Schwartz L. Inferior infarction following alcohol septal ablation: a consequence of “collateral damage”? Catheter Cardiovasc. Interv.69, 236–242 (2007).
   PubMed Web of Science ®Google Scholar
• Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Septal myectomy for obstructive hypertrophic cardiomyopathy. Op. Tech. Thorac. Cardiovasc. Surg.9, 278–292 (2004).
   Google Scholar
• Valeti US, Nishimura RA, Holmes DR et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol.49, 350–357 (2007).
   PubMed Web of Science ®Google Scholar
• Delling FN, Sanborn DY, Levine RA et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy. Am. J. Cardiol.100, 1691–1695 (2007).
   PubMed Web of Science ®Google Scholar
• Ralph-Edwards A, Woo A, McCrindle BW et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J. Thorac. Cardiovasc. Surg.129, 351–358 (2005).
   PubMed Web of Science ®Google Scholar
• Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation90, 2731–2742 (1994).
   PubMed Web of Science ®Google Scholar
• Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet339, 1318–1323 (1992).
   PubMed Web of Science ®Google Scholar
• Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am. J. Cardiol.83, 903–907 (1999).
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J. Am. Coll. Cardiol.29, 435–441(1997).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Dearani JA, Ommen SR et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.44, 2044–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Elbardissi AW, Dearani JA, Nishimura RA, Ommen SR, Stulak JM, Schaff HV. Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy. Mayo Clin. Proc.82, 1516–1524 (2007).
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Buergler JM, Quinones MA, Spencer WH 3rd, Lawrie GM. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol.50, 795–798 (2007).
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc. Interv.66, 375–389 (2005).
   PubMed Web of Science ®Google Scholar